{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"11.1","value":"4.6"},{"groupId":"OG001","lowerLimit":"6.0","upperLimit":"12.3","value":"8.2"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG002","lowerLimit":"11.3","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"67"}],"units":"Participants"}],"description":"Progression-free Survival (PFS) is defined as the time from start of treatment to IRC determined disease progression or death due to any cause. Patients who were lost to follow-up prior to documentation of disease progression and patients who were alive without disease progression before a data analysis cut-off date were censored at the last disease assessment.\n\nMedian PFS was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants previously treated with bortezomib received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.","id":"OG000","title":"Part 1: Carfilzomib 20 mg/m²"},{"description":"Participants not previously treated with bortezomib received carfilzomib 20 mg/m² IV injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.","id":"OG001","title":"Part 2: Carfilzomib 20 mg/m²"},{"description":"Participants not previously treated with bortezomib received carfilzomib 20 mg/m² IV on Days 1, 2, 8, 9, 15, and 16 of Cycle 1. If all doses were well-tolerated the dose was escalated to 27 mg/m² IV on Days 1, 2, 8, 9, 15, and 16 for subsequent cycles, for up to 12 cycles.","id":"OG002","title":"Part 2: Carfilzomib 20/27 mg/m²"}],"paramType":"MEDIAN","populationDescription":"Response Evaluable Population","reportingStatus":"POSTED","timeFrame":"Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 30 November 2010 for Part 1 and 22 April 2011 for Part 2. Median follow-up time was 13.4 months for Part 1 and 11.5 months in Part 2.","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}